INmune Bio Inc. Common stock (INMB) Stock Price

INMBStock

$2.43−2.07%52W

Market Cap$67.44M

P/E—

PEG Ratio—

Div yield—

Beta0.88

INMB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)63.57%

Price vs S&P 500 (4W)34.96%

VGM Score61.31

Book Value / Share (Quarterly)$0.74

P/TBV (Annual)1.76x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-48.68%

Cash Flow / Share (Quarterly)$-0.76

Price vs S&P 500 (YTD)39.32%

Net Profit Margin (TTM)-19478.00%

EPS (TTM)$-1.69

10-Day Avg Trading Volume0.38M

EPS Excl Extra (TTM)$-1.69

Revenue Growth (5Y)37.97%

EPS (Annual)$-1.86

ROI (Annual)-195.26%

Net Profit Margin (5Y Avg)-87209.13%

Cash / Share (Quarterly)$0.80

ROA (Last FY)-141.98%

Revenue Growth TTM (YoY)257.14%

EBITD / Share (TTM)$-1.67

ROE (5Y Avg)-97.66%

Operating Margin (TTM)-19810.00%

Cash Flow / Share (Annual)$-0.89

P/B Ratio2.98x

P/B Ratio (Quarterly)1.53x

Net Income / Employee (Annual)$-2,187,300

EV / Revenue (TTM)744.05x

Net Interest Coverage (TTM)-52.34x

ROA (TTM)-128.78%

EPS Incl Extra (Annual)$-1.86

Current Ratio (Annual)3.55x

Quick Ratio (Quarterly)4.11x

3-Month Avg Trading Volume0.63M

52-Week Price Return-2.07%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.88

P/S Ratio (Annual)1171.21x

Asset Turnover (Annual)0.00x

52-Week High$2.48

Operating Margin (5Y Avg)-88339.48%

EPS Excl Extra (Annual)$-1.86

Tangible BV CAGR (5Y)1.12%

26-Week Price Return74.81%

Quick Ratio (Annual)3.48x

13-Week Price Return63.89%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.24x

Enterprise Value$37.20M

Revenue / Share Growth (5Y)20.11%

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-21.00%

Revenue / Employee (Annual)$2,400

Pretax Margin (Annual)-91866.00%

Cash / Share (Annual)$0.93

3-Month Return Std Dev73.52%

Net Income / Employee (TTM)$-1,981,000

ROE (Last FY)-195.26%

Net Interest Coverage (Annual)-52.22x

EPS Basic Excl Extra (Annual)$-1.86

Receivables Turnover (TTM)0.07x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.69

Receivables Turnover (Annual)0.05x

ROI (TTM)-170.86%

P/S Ratio (TTM)1171.21x

Pretax Margin (5Y Avg)-87209.13%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.88

Price vs S&P 500 (52W)-20.39%

Year-to-Date Return51.28%

5-Day Price Return11.85%

EPS Normalized (Annual)$-1.86

ROA (5Y Avg)-72.94%

Net Profit Margin (Annual)-91866.00%

Month-to-Date Return34.86%

EBITD / Share (Annual)$-1.91

Operating Margin (Annual)-94766.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-91.47%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.69

P/TBV (Quarterly)1.76x

P/B Ratio (Annual)1.76x

Pretax Margin (TTM)-19478.00%

Book Value / Share (Annual)$0.88

Price vs S&P 500 (13W)61.10%

Beta0.88x

Revenue / Share (TTM)$0.00

ROE (TTM)-170.86%

52-Week Low$1.09

vGradeD

gGradeA

mGradeB

vgmGradeB

INMB Earnings Surprise History

Q2 25-0.34est. -0.38

Q3 25-0.24est. -0.33

Q4 25-0.18est. -0.27

Q1 26-0.20est. -0.18

Q2 26-0.05est. -0.20

INMB Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.10

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
INMBINmune Bio Inc. Common stock	D	A	B	$2.43
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About INmune Bio Inc. Common stock

INmune Bio is a clinical-stage biotechnology company developing immunotherapies designed to reprogram patients' innate immune systems to combat cancer. The company's pipeline includes multiple candidates across oncology and other therapeutic areas, positioned to address significant unmet medical needs in immuno-oncology.